Abstract
Introduction A relationship between long-term metformin use and vitamin B12 deficiency has been long discussed in literature. Nonetheless, prior to 2022, there was no official guidance. In June 2022, the MHRA published advice, stating that low vitamin B12 is now considered to be a common side effect. It advises checking levels in patients with symptoms of B12 deficiency, as well as monitoring those at risk of B12 deficiency.
Despite efforts to promote evidence-based practice, there is still a gap in the translation of research findings into policies and clinical practice. The above research has been shared widely in the academic and specialist Diabetes literature over a prolonged period. The purpose of the scoping review is to explore what evidence is available regarding clinicians’ awareness of the association between metformin use and vitamin B12 deficiency in patients with T2DM and how this evidence is implemented into frontline clinical practice and what screening processes are recommended or exist?
Methods and analysis This is a protocol for a scoping review to be guided by the Joanna Briggs Institute (JBI) methodology for scoping reviews 20. The databases to be searched will include CINAHL, MEDLINE, EMBASE, British Nursing Index, via EBSCOhost. Sources of unpublished studies, policies and grey literature will include Google Scholar, the Cochrane Library, ProQuest Dissertations and Theses Open. Titles and abstracts of articles were reviewed by the authors. If articles were representative of the inclusion criteria, the articles went through a full-text review by the authors The results of the search and study inclusion/exclusion process will be reported and presented in a Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram. Data will be extracted from papers, using the recommended JBI data extraction tool.
Strengths and limitations of this study
To the authors’ knowledge, this is the first scoping review to look at clinician awareness of Vitamin B12 deficiency in long term metformin use.
Strengths include an extensive search of multiple databases, including grey literature.
As this is a scoping review, the quality of the evidence and risk of bias will not be evaluated.
The review is also limited to selected languages which may bias the evidence.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Competing Interest Statement All authors have completed the Unified Competing Interest form (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work.
Transparency declaration I can confirm as the lead author and the manuscript’s guarantor that the manuscript is an honest, accurate, and transparent account of the protocol created; that no important aspects of the process have been omitted.
Ethical approval No ethical approval was required.
Sponsor University of Bath- The University of Bath is the sponsor of this project. This project is being undertaken as part of a Post Doctoral study through the University of Bath. The lead author is being supervised by an employee of the University of Bath throughout the entirety of the project. The research study and design has been approved through academic peer review. The University of Bath are not providing any funding towards this project.
Statement of independence of researchers from funders There is no external funding for this project and the authors can confirm the authors creating the protocol study were free to design the protocol without undue influence from any organisation or individual providing financial support.
Patient and Public involvement As this was the development of a scoping review protocol, it was not deemed appropriate to involve any representatives of patients or members of the public.
Patient consent for publication Not applicable.
Data sharing statement Data sharing is not applicable as no datasets generated and/or analysed for this study
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos